The incidence of gastrointestinal perforations among rheumatoid arthritis patients
Open Access
- 21 October 2010
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (2), 346-351
- https://doi.org/10.1002/art.30107
Abstract
Objective Gastrointestinal (GI) perforation has emerged as a novel safety concern in relation to medications used to treat rheumatoid arthritis (RA). This study was undertaken to characterize the incidence and risk factors for GI perforation in RA patients. Methods Using administrative databases of a large US health plan, we identified RA patients treated with biologic agents, methotrexate (MTX), oral glucocorticoids, and nonsteroidal antiinflammatory drugs (NSAIDs). Additional risk factors we evaluated included diverticulitis. Hospitalization with GI perforation was identified using a validated algorithm. Incidence rates and risk factors were evaluated using Cox proportional hazards models. Results Among 40,841 RA patients, 37 hospitalizations with GI perforation were identified. The rate of GI perforation among patients currently being treated with biologic agents who were also receiving oral glucocorticoids was higher (1.12 per 1,000 person‐years [95% confidence interval (95% CI) 0.50–2.49]) than for patients being treated with biologic agents who were not also receiving glucocorticoids (0.47 per 1,000 person‐years [95% CI 0.22–0.98]) or for patients being treated with MTX who were also receiving glucocorticoids (0.87 per 1,000 person‐years [95% CI 0.36–2.10]). Neither biologic agents nor MTX was significantly associated with GI perforation, in contrast to current treatment with glucocorticoids and NSAIDs together (hazard ratio 4.7 [95% CI 1.9–12.0]) or glucocorticoids alone (hazard ratio 2.8 [95% CI 1.3–6.1]). Diverticulitis also was a strong risk factor (hazard ratio 9.1 [95% CI 3.1–26.4]). Seventy percent of patients with GI perforation received glucocorticoids, had antecedent diverticulitis, or both. Conclusion GI perforation is an uncommon but serious adverse event among RA patients. Because a majority of patients with GI perforation were being treated with glucocorticoids or had previously experienced diverticulitis, these individuals should be considered at higher risk.Keywords
This publication has 13 references indexed in Scilit:
- A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis RegistriesSeminars in Arthritis and Rheumatism, 2010
- Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studiesArthritis & Rheumatism, 2007
- Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study.2006
- Evaluating Medication Effects Outside of Clinical Trials: New-User DesignsAmerican Journal of Epidemiology, 2003
- Risk communication in rheumatoid arthritis.2003
- Serious lower gastrointestinal clinical events with nonselective NSAID or coxib useGastroenterology, 2003
- Unwillingness of rheumatoid arthritis patients to risk adverse effectsRheumatology, 2002
- Incidence of serious upper gastrointestinal bleeding/perforation in the general population:Journal of Clinical Epidemiology, 2002
- The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.2000
- Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory DrugsAnnals of Internal Medicine, 1991